FreeCME

The Future of Treatment for Patients with Meibomian Gland Dysfunction-Associated DED

CME: 1.0

November 30, 2021
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This online educational activity is directed toward ophthalmologists, optometrists and other healthcare professionals who would be involved in dry eye disease care, such as PCPs, NPs and PAs.

Program Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of meibomian gland dysfunction (MGD)-associated dry eye disease (DED), with a forward-looking perspective on how new and novel agents may impact clinical practice. An overview of MGD and its association with DED as well as current and emerging treatment strategies will be presented in a multimedia format, including a series of video interviews with expert thought leaders integrated into text-based elements.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the impact that MGD-associated DED has on patients’ QoL
  • Summarize the efficacy and safety of currently available agents used for the treatment of MGD-associated DED
  • Describe the MOAs of agents under investigation for the treatment of MGD-associated DED
  • Analyze clinical trial data for investigational agents in the treatment of MGD-associated DED

Post a comment to this article